Accordingly, the induced exogenous cyclin D2 in trametinib-sensitive MM cells clearly performed to compensate for the reduction in endogenous cyclin D1 and cyclin D2, thereby conferring a resistance. Here, CCND2 is linked to Miyoshi myopathy.